Aardvark Therapeutics (AARD) Income from Continuing Operations (2024 - 2026)
Aardvark Therapeutics (AARD) reported Income from Continuing Operations of 21575000.0 for Q1 2026, down 132.09% on a YoY basis from 67234730.14 in Q1 2025, and down 22.73% sequentially from 17579000.0 in Q4 2025.
Aardvark Therapeutics (AARD) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Aardvark Therapeutics (AARD) has 3 years of Income from Continuing Operations data on file, last reported at 21575000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 132.09% year-over-year to 21575000.0; the trailing twelve-month figure through Mar 2026 stood at 69882000.0 (down 127.08% YoY), and the FY2025 full-year result was 69946000.0, down 80.24% from the prior year.
- Income from Continuing Operations fell to 21575000.0 in Q1 2026, from 17579000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 2068000.0 in Q1 2024 to a low of 21575000.0 in Q1 2026.
- A 3-year average of 11413777.78 and a median of 11908000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 47.62% in 2025, while the deepest fall reached 349.52% in 2025.
- Tracing AARD's Income from Continuing Operations over 3 years: stood at 11908000.0 in 2024, then tumbled by 47.62% to 17579000.0 in 2025, then decreased by 22.73% to 21575000.0 in 2026.
- Business Quant data shows AARD's Income from Continuing Operations at 21575000.0 in Q1 2026, 17579000.0 in Q4 2025, and 16352000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Aardvark Therapeutics | 139.40 Mn | 19.44 Mn | - | -21.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.58 Mn |
| Dec 31, 2025 | -17.58 Mn |
| Sep 30, 2025 | -16.35 Mn |
| Jun 30, 2025 | -14.38 Mn |
| Mar 31, 2025 | -9.30 Mn |
| Dec 31, 2024 | -11.91 Mn |
| Sep 30, 2024 | -4.09 Mn |
| Jun 30, 2024 | -5.48 Mn |
| Mar 31, 2024 | -2.07 Mn |